权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Role of the ER stress transcription factor XBP1S in the development of idiopathic pulmonary fibrosis

ER应激转录因子XBP1S在特发性肺纤维化发展中的作用

基本信息

批准号：
10524052
负责人：
Gang Chen
金额：
$ 41.72万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-12-15 至 2025-11-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10524052
关键词：
3-Dimensional Affect Aging Alleles Alveolus Apoptosis Binding Binding Proteins Biochemical Biological Assay Bleomycin Cell physiology Cells Cellular Stress Cyst Data Defect Development Disease Progression Distal Early Diagnosis Electrophysiology (science)Environmental Risk Factor Epithelial Cells Epithelium Etiology Exposure to Factor X Fibroblasts Fibrosis Functional disorder Gene Expression Genes Genetic Genotype Host Defense Hypoxia Impairment In Vitro Individual Infection Inflammation Influenza Influenza A Virus, H1N1 Subtype Injury Laboratories Lead Lung Lung diseases MUC5B gene Maintenance Mediating Messenger RNA Minor Modeling Mucins Mucociliary Clearance Mucous body substance Mus Mutation Myofibroblast Natural regeneration Onset of illness Peripheral Persons Phenotype Predisposition Probability Production Proteins Pulmonary Fibrosis RNA Splicing Risk Risk Factors Role Signal Transduction System Telomerase Testing Time Variant XBP1 gene airway epithelium airway remodeling alveolar epithelium alveolar type II cell biophysical properties effective therapy endoplasmic reticulum stress epithelial injury genetic variant human model idiopathic pulmonary fibrosis in vitro Assay in vivo injury and repair lung repair mouse genetics mouse model notch protein novel novel marker overexpression prevent progenitor promoter repaired response response to injury stem cell function stem cell homeostasis stem cells surfactant therapeutic target transcription factor

项目摘要

Idiopathic pulmonary fibrosis (IPF) is a progressive and end-stage lung disease of unknown etiology and no cure. It is likely that genetic changes increase a person's risk of developing IPF, and then exposure to certain environmental factors and/or aging trigger the onset of the disease. The MUC5B promoter variant rs35705950 is present in ∼50% of individuals with IPF and is recognized as the strongest known risk factor (genetic and otherwise) for the development of IPF. This variant leads to overexpression of MUC5B mRNA and protein in both distal airway epithelia and honeycomb cysts in the peripheral lung. These observations raise the question of why excessive MUC5B expression in distal airways is associated with IPF? Recently, our laboratory identified for the first time that the ER stress transcription factor XBP1S is highly expressed in the epithelium lining the distal airways and honeycomb cysts of IPF lung, activates MUC5B gene expression by direct binding to its promoter. Further, XBP1S differentially regulating the MUC5B promoter variant. These data connected activation of ER stress with excessive MUC5B expression in a promoter variant-dependent model likely impairs mucociliary clearance and function of distal airway stem cells that increase susceptibility of development of pulmonary fibrosis. We hypothesize that activation of XBP1S induces MUC5B expression in the distal airways that promotes pulmonary fibrosis. To test this central hypothesis, we propose the following aims: 1) XBP1S- mediated MUC5B secretion in distal airway epithelium enhances susceptibility to development of pulmonary fibrosis in vivo. We will assess the role of XBP1S by exposing Xbp1 airway epithelium-specific overexpression or deletion mice to bleomycin induced respiratory epithelial injury. 2) XBP1S-mediated MUC5B secretion impairs distal airway stem cell function to repair peripheral lung epithelia after injury. We will utilize mouse airway epithelium-lineage tracing system and in vitro 2-D and 3-D differentiation assays to evaluate the role of XBP1S and mucin in maintenance of the airway stem cell homeostasis in response to injury. 3) Activation of XBP1S and presence of MUC5B promoter variant cause abnormal mucus secretion, impaired mucociliary clearance and activation of myofibroblast differentiation. We will analyze the biochemical and biophysical properties of the secreted mucus and electrophysiology of the DAE carrying the MUC5B promoter variant rs35705950 at baseline and after activation of ER stress. We will also test whether XBP1S-expressing DAE carrying the MUC5B promoter variant and/or hypoxia-induced epithelial injury directly promotes myofibroblast differentiation. Completing the aims proposed in this application will provide novel mechanisms underlying ER stress-mediated excessive mucin secretion by DAE promotes pulmonary fibrosis. These mechanistic studies will likely identify novel biomarkers for early diagnosis as well as therapeutic targets (e.g., suppression of XBP1S activation as a promising approach to resolve MUC5B hypersecretion, even for those carrying the MUC5B promoter variant) in the distal lung to prevent or reverse fibrotic disease progression.

特发性肺纤维化（IPF）是一种病因不明的进行性终末期肺部疾病